

**Brandes Investment Partners**  
**U.S. Small Cap Value Equity Strategy Notes**  
**Third Quarter 2024 (1 July – 30 September 2024)**

The Brandes U.S. Small Cap Value Equity Strategy returned 8.63% (gross of fees), underperforming its benchmark, the Russell 2000 Index, which was up 9.27% in the quarter. The Russell 2000 Value Index gained 10.15%.

**Positive Contributors**

Leading contributors included holdings in the health care and information technology sectors: networking products company NETGEAR, Phibro Animal Health, blood plasma company Grifols, and Pediatrix Medical Group.

In July, Grifols confirmed that the founding family, which controls 30% of the company, and Brookfield, a multinational Canadian investment fund, are evaluating a potential joint takeover bid for the entire business. The structure and pricing remain unclear, but the market reacted positively to the news.

In September, NETGEAR revised its guidance upward after it entered into a settlement with TP-Link regarding pending patent infringement disputes. NETGEAR received a \$135 million settlement and all pending litigation between the two parties will be dismissed or no longer pursued. NETGEAR also announced an earlier-than-anticipated 5G mobile hotspot launch.

Other contributors included regional jet manufacturer Embraer, apparel business Hanesbrands, and aerospace and defense company Moog Inc.

**Performance Detractors**

Notable detractors were in the industrials, consumer staples, and energy sectors, specifically Innovex International, Edgewell Personal Care Co., and Orion Group.

Orion announced a \$25 million equity raise, with plans to use the net proceeds for working capital and debt repayment. The decision to raise capital was driven partly by a delay in Orion's \$30-million land sale agreement, which has taken longer than expected to close. Additionally, Orion's balance sheet has been under pressure over the past two quarters due to expanding working capital needs, stemming from a six-month delay on a large U.S. Navy project where Orion is a subcontractor. We believe the capital raise was a prudent move as it provides the company with greater control over its destiny while awaiting the land deal closure and a reversal in the working capital cycle. It should also allow Orion to participate in the upcoming infrastructure cycle inflection mostly intact.

Other detractors included juvenile and home products company Dorel Industries and security system technology business Arlo Technologies, which undid some of its strong performance earlier in the year.

On a relative basis, our underweight to the financials and real estate sectors, two of the strongest performers, detracted from returns.

**Select Activity in the Quarter**

We initiated positions in metalworking business MSC Industrial Direct, biotechnology company Grifols, aviation training equipment company CAE, and carbon fiber composite producer Hexcel.

CAE supplies simulation equipment and integrated pilot training services to both civil and military aviation customers. Competing in a market dominated by two key players (the other being Flight Safety), CAE boasts the world's largest installed base of full-flight simulators.

During the past 20 years, CAE has diversified into the less-cyclical pilot training business, offering training services through a global network of more than 250 civil and military training locations across 40 countries. The company derives 40% of its revenues from simulation products and 60% from training and services.

Our coverage of CAE began in 2011, and since then, our assessment of the company's core franchise quality has remained unchanged. Notably, during the COVID-19 pandemic, CAE took significant steps to strengthen its

competitive position and improve its industrial structure. First, CAE leveraged its financial strength to complete a series of opportunistic acquisitions, buying nine companies at what we deemed were appealing prices. Doing so helped CAE consolidate its end-markets and expand its capabilities. Second, it restructured its cost base, closing nine plants and removing \$70 million in annualised costs, which resulted in a 1.5% margin benefit on sales. Lastly, CAE expanded its relationship with mainline airlines, which chose to outsource an increasing share of their training needs. To satisfy this new demand, CAE embarked on a heavy capital expenditure cycle over the pandemic that we believe will benefit shareholders in the years ahead.

The opportunity to initiate a position in CAE came as investors expressed concern about recent margin weakness in the company's defense segment. However, we view these challenges as temporary. Inflation and supply chain pressures have started to ease. Many of CAE's under-earning, fixed-price contracts are set to expire by 2025. We expect that CAE is well positioned to improve its profitability as legacy fixed-priced contracts roll over and as new higher-margin defense contracts begin to ramp up. The company has given guidance for mid-double-digit margins on new contracts versus mid-single digits on legacy fixed-price contracts that were affected by pandemic-related cost pressures.

CAE's investment case is supported by its dominant position in flight simulation and pilot training services that offer moat-like characteristics, strong free cash flow and high tangible returns on capital with favorable medium-term growth characteristics. The company can also access attractive financing through perpetual, zero-cost loans from the Canadian government for research and development initiatives.

Founded in 1946, Hexcel (HXL) is a manufacturer of carbon fiber composite materials and composite engineered structures for commercial aerospace, defense, space, and industrial end-markets. HXL's composites are a key input for a variety of applications, including aerostructures (wings, fuselage, engine casings), primary structures on spacecraft, and carbon ceramic brakes for high-performance cars. About 90% of its revenues comes from aerospace programs (commercial and defense), with HXL active on all modern Airbus and Boeing platforms, as well as over 100 defense programs.

Since the pandemic, HXL has faced industry-wide skilled-labor shortages, supply-chain bottlenecks, and input cost inflation. These challenges have slowed the production ramp on key commercial platforms and compressed HXL's margins as the company operates under fixed-price contracts. Additionally, HXL had increased capacity ahead of the production ramp and thus has been operating at suboptimal efficiency on a substantial fixed-cost base. While these headwinds have started to ease and HXL fundamentals have moved closer to pre-pandemic levels, lingering supply-chain issues in recent months have slowed production on commercial aerospace platforms at Airbus and Boeing, prompting questions about the pace of normalization. The outlook has been further dampened by regulatory hurdles and the Boeing labor strike, though it should be noted that HXL's commercial exposure is primarily to Airbus.

Despite the supply-chain issues starting to alleviate, the market seems to extrapolate HXL's prospects from its short-term challenges, causing its share price to fall. However, we expect the environment to gradually normalise and HXL to resume its recovery to pre-pandemic levels. Among aerospace composite manufacturers, HXL holds a leading market share and is the most vertically integrated player, with strong capabilities throughout the value chain. There is also potential for secular growth from new aircraft designs that will incorporate more carbon fiber content as the industry seeks to reduce emissions. This should bode well for demand for HXL's products in the long term. Furthermore, we appreciate HXL's attractive financial characteristics, including a solid balance sheet, healthy free-cash-flow generation, and an operating culture focused on return on invested capital metrics. At its current valuations, HXL offers an appealing risk/reward to us.

Other portfolio activity included full sales of insurer Mercury General, multi-utility Avista, and biotechnology company United Therapeutics.

### **Year-to-Date Briefing**

The Brandes U.S. Small Cap Value Equity Strategy returned 18.44% (gross of fees), outperforming its benchmark, the Russell 2000 Index, which gained 11.17% in the nine months ended 30 September 2024, as well as the Russell 2000 Value Index, which was up 9.22%.

Holdings in the industrials, materials, health care, and information technology sectors drove returns. At the holding level, leading performers included aerospace and defense companies Embraer and Moog, machinery business Graham Corporation, NETGEAR, Arlo Technologies, and Phibro Animal Health.

Investments in the energy and consumer staples sectors were notable decliners, specifically energy equipment business Innovex International and Ingles Markets. Other detractors included insurer Crawford & Company, Utah Medical Products, and Park Aerospace.

### **Current Positioning**

With the additions of CAE, Hexcel, and MSC Industrial Direct, the strategy's allocation to the industrials sector increased, and industrials continues to be the largest weighting and relative overweight from a sector standpoint. The portfolio also maintains large weights in the health care and information technology sectors (although underweight relative to the benchmark in these two categories). The strategy's most notable underweights are in financials, consumer discretionary, and real estate. Compared to the Russell 2000 Value Index, we have significantly less exposure to financials and real estate.

In our opinion, the differences between the Brandes U.S. Small Cap Value Equity Strategy and the broader U.S. small-cap market continue to make it an attractive complement to other small-cap offerings. Our strategy exhibits lower valuations than the Russell 2000 Index, while offering exposure to companies that we believe have strong balance sheets, compelling growth prospects, and a history of durable free-cash-flow generation.

We are optimistic about the potential of value stocks in general and believe the Brandes U.S. Small Cap Value Equity Strategy remains well positioned from a long-term risk/reward perspective.

Term definitions: <https://www.brandes.com/termdefinitions>

The Russell 2000 Index with gross dividends measures the performance of the small cap segment of the U.S. equity universe.

The Russell 2000 Value Index with gross dividends measures performance of the small cap value segment of the U.S. equity universe. Securities are categorised as growth or value based on their relative book-to-price ratios, historical sales growth, and expected earnings growth.

Diversification does not assure a profit or protect against a loss in a declining market.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Unlike bonds issued or guaranteed by the U.S. government or its agencies, stocks and other bonds are not backed by the full faith and credit of the United States. Stock and bond prices will experience market fluctuations. Please note that the value of government securities and bonds in general have an inverse relationship to interest rates. Bonds carry the risk of default, or the risk that an issuer will be unable to make income or principal payment. There is no assurance that private guarantors or insurers will meet their obligations. The credit quality of the investments in the portfolio is not a guarantee of the safety or stability of the portfolio. Investments in Asset Backed and Mortgage Backed Securities include additional risks that investors should be aware of such as credit risk, prepayment risk, possible illiquidity and default, as well as increased susceptibility to adverse economic developments. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

**Ireland/Europe:** FOR PROFESSIONAL INVESTOR USE ONLY. Issued by Brandes Investment Partners (Europe) Limited (Brandes Europe), Alexandra House, The Sweepstakes, Ballsbridge, Dublin, D04 C7H2, Ireland. Registered in Ireland Number 510203. Authorised and regulated by the Central Bank of Ireland. This report is being provided for information purposes only, no representation or warranty is made, whether express or implied as to the accuracy or completeness of the information provided. To the fullest extent permitted by law Brandes Europe shall not be liable for any loss or damage suffered by any person as a result of the receipt of this report. Recipients of this report should obtain their own professional advice. The distribution of this report may be restricted by law. No action has been or will be taken by Brandes Europe to permit the possession or distribution of this report in any jurisdiction where action for that purpose may be required. Accordingly, this report may not be used in any jurisdiction except under circumstances that will result in compliance with any applicable laws and regulations. Persons to whom this report is communicated should inform themselves about and observe any such restrictions. This information is being issued only to, and/or is directed only at (i) persons who have professional experience in matters relating to investments or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This report is a confidential communication to, and solely for the use of, the persons to whom it is distributed to by Brandes Europe.

